• REGENCY: Obinutuzumab’s Promise for Lupus Nephritis

  • Feb 28 2025
  • Length: 54 mins
  • Podcast

REGENCY: Obinutuzumab’s Promise for Lupus Nephritis

Listen for free

View show details

  • Summary

  • Join Dr Raquel Faria and Professors Richard Furie and Maria Dall’Era as they discuss the results of the phase 3 REGENCY trial of obinutuzumab for the treatment of lupus nephritis.This episode explores what obinutuzumab could mean for the future management of lupus nephritis.

    Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.
    Show more Show less
Show more Show less
adbl_web_global_use_to_activate_webcro768_stickypopup

What listeners say about REGENCY: Obinutuzumab’s Promise for Lupus Nephritis

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available